Intellia Therapeutics (NASDAQ:NTLA) CAO Michael Dube Sells 1,871 Shares

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael Dube sold 1,871 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total value of $32,517.98. Following the completion of the transaction, the chief accounting officer owned 55,266 shares of the company’s stock, valued at approximately $960,523.08. This trade represents a 3.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Intellia Therapeutics Trading Down 2.3%

NTLA opened at $19.96 on Friday. The stock has a fifty day simple moving average of $12.88 and a two-hundred day simple moving average of $10.31. The company has a market cap of $2.14 billion, a price-to-earnings ratio of -4.26 and a beta of 2.37. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $21.47.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.04. The business had revenue of $14.25 million during the quarter, compared to the consensus estimate of $12.26 million. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The firm’s quarterly revenue was up 104.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.52) earnings per share. On average, analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors have recently modified their holdings of the business. Cambridge Investment Research Advisors Inc. boosted its position in shares of Intellia Therapeutics by 51.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company’s stock valued at $140,000 after buying an additional 6,722 shares during the last quarter. D.A. Davidson & CO. boosted its position in shares of Intellia Therapeutics by 76.2% during the first quarter. D.A. Davidson & CO. now owns 26,020 shares of the company’s stock valued at $185,000 after buying an additional 11,250 shares during the last quarter. Voya Investment Management LLC boosted its position in shares of Intellia Therapeutics by 621.5% during the first quarter. Voya Investment Management LLC now owns 208,009 shares of the company’s stock valued at $1,479,000 after buying an additional 179,180 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Intellia Therapeutics by 4.1% during the fourth quarter. California State Teachers Retirement System now owns 90,638 shares of the company’s stock valued at $1,057,000 after buying an additional 3,596 shares during the last quarter. Finally, Ballentine Partners LLC purchased a new stake in shares of Intellia Therapeutics during the second quarter valued at $161,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on NTLA shares. JMP Securities reiterated a “market perform” rating on shares of Intellia Therapeutics in a report on Friday, September 19th. Chardan Capital decreased their price objective on Intellia Therapeutics from $68.00 to $60.00 and set a “buy” rating for the company in a report on Monday, August 11th. Wells Fargo & Company reiterated an “overweight” rating and issued a $45.00 price objective (down previously from $50.00) on shares of Intellia Therapeutics in a report on Friday, August 8th. Royal Bank Of Canada reduced their price target on Intellia Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a report on Friday, August 8th. Finally, Guggenheim restated a “buy” rating and set a $14.00 price target on shares of Intellia Therapeutics in a report on Wednesday, August 13th. Eleven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $27.39.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.